Journey Medical Corp Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Journey Medical Corp (DERM) performed this year. Instead of digging through legal filings, we’ll break down the business so you can decide if it fits your investment goals.

1. What does this company do?

Journey Medical is a pharmaceutical company focused on skin health. They use a "hub-and-spoke" model: they acquire late-stage drugs and use a specialized sales team to bring them to market. Their portfolio includes Qbrexza (for excessive sweating), Amzeeq and Zilxi (for acne and rosacea), and Accutane (for severe acne). They reach U.S. dermatologists through a dedicated sales force of about 70–80 representatives.

2. Financial performance

In 2024, Journey Medical earned $128.5 million in revenue, up from $118.6 million in 2023. This is an 8.3% increase. Despite this growth, the company lost $35.2 million. They fund operations by licensing their drugs internationally; for example, their deal with Cutia Therapeutics for Amzeeq in Greater China provides payments that help cover their research and sales costs.

3. Major wins and challenges

• New Product Hope: The FDA approved Emrosi in April 2024 to treat rosacea. Management believes this "blockbuster" drug could lead the company to profit by taking market share from existing treatments.
• Debt Management: The company holds about $65 million in long-term debt. They recently extended their loan deadlines to ensure they have enough cash to fund the Emrosi launch.
• The Challenge: The company relies on just a few products for most of its income. If Emrosi fails to gain insurance coverage or faces supply issues, the company’s cash flow will suffer significantly.

4. Financial health

This is the most critical area to watch. The company warned there is "substantial doubt" about its ability to stay in business. They ended 2024 with $18.4 million in cash. Because they are spending money quickly to launch Emrosi and pay off debt, this cash won't last 12 months. They will likely need to raise more money, which means issuing more shares and reducing your ownership percentage.

5. Key risks

• Going Concern Risk: Because the company loses money and has little cash, it depends on outside funding or a massive sales boost from Emrosi to survive.
• Generic Competition: Cheaper, generic versions of their older drugs are hitting the market, forcing Journey to lower prices and compete for customers.
• Control: Fortress Biotech owns about 60% of the voting power. They control board decisions, which means they may prioritize their own interests over those of smaller investors.

6. Future outlook

The company’s future depends entirely on how quickly doctors and insurers adopt Emrosi. If sales hit targets, the company hopes to stop losing money. If adoption is slow, they will likely need to borrow more or issue more shares, which would dilute the value of current holdings.

Final Thought for Investors: This is a high-risk, high-reward situation. Because of the "going concern" warning, this is not a "set it and forget it" investment. Before buying, consider whether you are comfortable with the company's need for rapid growth to offset its current cash shortage.